NuCana (NASDAQ:NCNA) Stock Rating Upgraded by Zacks Investment Research

Zacks Investment Research upgraded shares of NuCana (NASDAQ:NCNA) from a hold rating to a buy rating in a report issued on Saturday, Zacks.com reports. They currently have $11.00 target price on the stock.

According to Zacks, “NuCana PLC is a clinical-stage biopharmaceutical company. It focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The company’s pipeline of products includes Acelarin, NUC-3373 and NUC-7738 which are in clinical stage. NuCana PLC is based in EDINBURGH, United Kingdom. “

Several other equities research analysts also recently issued reports on the company. BidaskClub upgraded NuCana from a strong sell rating to a sell rating in a report on Wednesday, July 31st. William Blair restated an outperform rating on shares of NuCana in a report on Thursday, May 16th. Finally, ValuEngine upgraded NuCana from a hold rating to a buy rating in a report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and an average target price of $23.50.

NuCana stock opened at $9.09 on Friday. The business’s 50 day moving average is $9.48. The firm has a market cap of $306.15 million, a price-to-earnings ratio of -15.95 and a beta of 3.27. NuCana has a one year low of $7.53 and a one year high of $30.10.

NuCana (NASDAQ:NCNA) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.22). As a group, research analysts forecast that NuCana will post -1.14 EPS for the current year.

A number of hedge funds have recently bought and sold shares of NCNA. BlackRock Inc. increased its holdings in NuCana by 134,310.2% during the 2nd quarter. BlackRock Inc. now owns 608,878 shares of the company’s stock worth $6,320,000 after purchasing an additional 608,425 shares during the last quarter. Asymmetry Capital Management L.P. increased its holdings in shares of NuCana by 257.8% in the 2nd quarter. Asymmetry Capital Management L.P. now owns 162,414 shares of the company’s stock valued at $1,686,000 after acquiring an additional 117,021 shares during the last quarter. Marshall Wace North America L.P. increased its holdings in shares of NuCana by 558.8% in the 1st quarter. Marshall Wace North America L.P. now owns 60,843 shares of the company’s stock valued at $1,034,000 after acquiring an additional 51,607 shares during the last quarter. Rothschild Investment Corp IL increased its holdings in shares of NuCana by 126.1% in the 2nd quarter. Rothschild Investment Corp IL now owns 28,075 shares of the company’s stock valued at $291,000 after acquiring an additional 15,660 shares during the last quarter. Finally, Alps Advisors Inc. increased its holdings in shares of NuCana by 5.6% in the 1st quarter. Alps Advisors Inc. now owns 77,838 shares of the company’s stock valued at $1,323,000 after acquiring an additional 4,160 shares during the last quarter. Institutional investors own 38.09% of the company’s stock.

NuCana Company Profile

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; Phase Ib clinical trials for the treatment of patients with biliary cancer; and Phase III clinical trials for the treatment of pancreatic cancer.

Featured Story: How to start trading in the forex market?

Get a free copy of the Zacks research report on NuCana (NCNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.